MARKET WIRE NEWS

CERo Therapeutics Holdings Inc. (OTC : CERO) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company¿s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body¿s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.


Quote


Last:$0.0049
Change Percent: 2.08%
Open:$0.0049
Close:$0.0049
High:$0.0049
Low:$0.004
Volume:637,769
Last Trade Date Time:11/16/2026 03:26:54 pm

Stock Data


Market Cap:$927,071
Float:19,556,591
Insiders Ownership:56.15%
Institutions:30
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:www.cero.bio
Country:US
City:South San Francisco

Chart & Financials



Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about CERo Therapeutics Holdings Inc. (OTC: CERO).

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News